Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients

NCT04840355 | Recruiting

• 1 other identifier: LC2020L03
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

In recent years, immunotherapy has become one of the important treatments for malignant tumors. Among them, PD-1 inhibitors have been widely used in clinical practice, and have shown a significant survival benefits in many patients. However, the incidence of immune-related adverse reactions (irAEs) of PD-1 inhibitors is relatively high, and severe cases can even threaten patients's life. At present, irAEs have become a bottleneck and it is urgent to establish a prevention strategy for the prediction of irAEs. In this study, the investigators intends to use Sintilimab as the research drug. A prospective cohort study was carried out. Part of the sample which was used as a training set would be detected for producing a time-series multi-dimensional data such as differential genes, metabolites and immune factors. Then gene expression programming (GEP) was used to explore the irAEs recognition model. Then, based on this recognition model, internal verification ( part of samples from the center 1 ) and external verification ( part of samples from the center 2 and center 3 samples) are carried out to accurately predict the high-risk population of irAEs and realize the early-stage warning of Sintilimab induced- irAEs.

Conditions

Immune Related Adverse Events; PD-1

Outcome Measures

Primary Outcomes (1)

• irAEs

  degree of irAEs induced by Sintilimab Injection

  24 month

Study Arms (3)

Subjects with no irAEs

Drug: Sintilimab Injection

Subjects with degree 1-2 irAEs

Drug: Sintilimab Injection

Subjects with degree 3-4 irAEs

Drug: Sintilimab Injection

Interventions

Sintilimab Injection DRUG

The recommended dose for intravenous infusion is 200 mg on day 1.Courses repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity.

Subjects with degree 1-2 irAEs; Subjects with degree 3-4 irAEs; Subjects with no irAEs

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subjects with histologically or cytologically confirmed are prepared to receive Sintilimab treatment

You may qualify if:

• Age ≥18 and ≤75 years old;
• Subjects with histologically or cytologically confirmed are prepared to receive Sintilimab treatment;
• Life expectancy of at least 6 months;
• Eastern Cooperative Oncology Group (ECOG) PS status≤ 2 or Karnofsky (KPS) ≥ 60;
• No prior immune checkpoint inhibitor treatment
• Signed written informed consent before any study-related procedure;
• Adequate hematopoietic function as defined by an absolute neutrophil count ≥1.5×109 /L, platelet count≥80×109 /L, hemoglobin≥90 g/L
• Adequate hepatic function, defined as a total bilirubin level≤1.5 ×upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤2.5 × ULN in subjects without liver metastases, AST and ALT levels ≤5 × ULN in subjects with documented liver metastases;
• Adequate renal function, defined as serum creatinine (Cr)≤1.5×ULN or calculated creatinine clearance≥60ml/min (Cockcroft-Gault formula);
• Serum albumin ≥28g/L;
• Thyroid-stimulating hormone (TSH)≤1×ULN (if abnormal,subject with the normal levels of FT3 and FT4 can be enrolled).

You may not qualify if:

• Has active autoimmune disease;
• Severe heart, lung, brain, kidney, gastrointestinal or systemic diseases;
• has interstitial lung disease;
• Simultaneous use of drugs that can affect the results of this study;
• Treatment may interfere with the results of the study
• Allergy or intolerance to the study drug
• subject with unconsciousness and psychiatric disorder
• Pregnant and lactating women
• Subject with poison and alcohol abuse

Sponsors & Collaborators

• Guohui Li: lead

Study Sites (1)

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China

RECRUITING

MeSH Terms

Interventions

sintilimab

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Head of Pharmacy department

Study Record Dates

• First Submitted: April 7, 2021
• First Posted: April 12, 2021
• Study Start: February 26, 2021
• Primary Completion: November 14, 2025
• Study Completion: November 14, 2025
• Last Updated: December 27, 2024

Record last verified: 2024-12

Locations

CN (1)